Allergy immunotherapy (AIT) has evolved significantly over the last decade, triggered by the need for more evidence-based medicine. ALK has worked with the allergy community to develop the fields' most robust clinical trial programme, enrolling over 25,000 patients, enabling prescribing decisions to move from experience-based to evidence-based. But ideal-world evidence alone can only tell you so much.​

That is where our programme Real-world Evidence in Allergy (REWEAL) comes in, demonstrating how AIT works in the real world.

We focus on expanding the access for healthcare professionals and people living with allergies to evidence-based allergy immunotherapy as well as strengthening the evidence around burden of disease, disease modification, and new indications. Here you can explore more about our commitment to safety and efficacy of our treatment solutions for allergic disease, our key sublingual immunotherapy (SLIT) clinical trials and real-world evidence as well as sharing of our clinical data.

In compliance with industry guidelines, more information about all our clinical trials can be found via the freely public registries ClinicalTrials.gov and EudraCT as well as on the page Clinical data sharing.

Information about our clinical trials can be found via the freely public registries clinicaltrialregister.eu, clinicaltrials.gov or on this page Clinical trials synopses.

The allergy digital portal provides healthcare professionals with access to the latest information, medical education resources and personalised services on allergy immunotherapy, including easy access to product information, scientific literature and presentations, clinical data and much more.

The Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

Over the last few decades allergy has increased in prevalence to become the most common chronic disease in modern societies. The causes for this sudden change are not entirely clear, although they seem to be linked to ‘modern lifestyle’.

It appears that allergy immunotherapy is the only treatment to treat the cause, induce immunological tolerance and to prompt disease modification. Disease modification implies long term effect, prevention of asthma in children with allergic rhinitis and prevention of new allergies.

In ALK we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people with allergies all over the world.

Previous award ceremonies and winners

2019: Kornel Golebski, University of Amsterdam, the Netherlands

2005: Omid Akbari, Harvard University, United States of America 

2004: Christopher Lynn Kepley, Commonwealth University of Virginia, United States of America 

2003: Erika Ganglberger, University of Vienna, Austria 

2002: Miriam Fleur Moffatt, University of Oxford, United Kingdom 

2001: Eckard Hamelmann, Humboldt-University of Berlin, Germany 

2000: Mark Larché, Imperial College, London, United Kingdom